Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

February 1, 2024

https://www.globenewswire.com/news-release/2024/02/01/2821916/0/en/Acasti-Announces-Poster-Detailing-its-GTX-104-STRIVE-ON-Trial.html

PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (Nasdaq:ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that a poster outlining its pivotal Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405) has been accepted for presentation at the 2024 International Stroke Conference, to be held February 7-9, 2024 in Phoenix, AZ.

Read more at globenewswire.com

Related news for (ACST)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.